Ligand Pharma Tops Q2 EPS by 60c
- ByInvesting.com-
Ligand Pharma (NASDAQ:LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus...
Symbol | Exchange | Currency |
---|
Ligand Pharma (NASDAQ:LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus...
Ligand Pharma (NASDAQ:LGND) reported Q1 EPS of $0.76, $0.10 better than the analyst estimate of $0.66. Revenue for the quarter came in at $45.7 million versus the consensus...
Barclays (LON:BARC) analyst Balaji Prasad maintained a Buy rating on Ligand Pharma (NASDAQ:LGND) on Thursday, setting a price target of $185, which is approximately 22.74% above...
The U.S. government has started sending out the third round of direct stimulus checks to eligible Americans. For those readers who have decided to invest some or all of the...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported fourth-quarter 2019 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 68 cents. The...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported third-quarter 2019 adjusted earnings of 49 cents per share, which missed the Zacks Consensus Estimate of 65 cents. The...
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Neutral | Buy | Strong Buy | Strong Buy | Sell |
Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Summary | Sell | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
265.12 | 265.59 | 261.26 | +2.94 | +1.12% | 939.53K | NYSE | |||
8.09 | 8.12 | 7.85 | -0.28 | -3.31% | 3.37M | NYSE | |||
100.63 | 101.85 | 99.80 | -0.20 | -0.20% | 36.63M | NASDAQ | |||
31.61 | 31.66 | 30.71 | -1.14 | -3.48% | 3.97M | NYSE | |||
175.57 | 179.33 | 171.85 | +4.39 | +2.56% | 3.22M | NASDAQ | |||
4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
1.16 | 1.19 | 1.15 | -0.0500 | -4.13% | 1.63M | NYSE | |||
166.01 | 166.41 | 165.13 | +0.71 | +0.43% | 3.86M | NYSE | |||
45.31 | 45.49 | 44.78 | -0.95 | -2.05% | 1.09M | NYSE | |||
3.525 | 3.55 | 3.47 | -0.075 | -2.08% | 7.08M | NYSE | |||
1.07 | 1.09 | 1.05 | -0.0300 | -2.73% | 74.86K | NYSE | |||
134.82 | 134.86 | 132.25 | +0.81 | +0.60% | 1.30M | NYSE | |||
49.72 | 50.06 | 49.40 | -0.40 | -0.79% | 6.04M | NYSE | |||
7.33 | 7.385 | 6.73 | +0.460 | +6.70% | 3.35M | NYSE | |||
39.26 | 40.38 | 38.81 | -1.48 | -3.64% | 2.90M | NYSE |